Eleven studies explored the use of immunoPET imaging in the preclinical and clinical contexts of HNSCC, each targeting specific immune-related biomarkers: PD-L1, epidermal growth factor receptor (EGFR), tenascin-c, extra domain b (ED-B), and cluster of differentiation 44 variant 6 (CD44v6), all within the context of HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.